Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sativex withdrawal study in MS spasticity
NCT00702468Phase 3Completed
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Nov 2007
- Primary completion
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cannabidiol in spasticity, sponsored by Jazz Pharmaceuticals plc. Primary endpoint: Number of Subjects Who Experience Treatment Failure at Week 5. Started Nov 2007; status: completed.
02
Drugs
cannabidiol
03
Conditions
spasticity
Beyond the preview
Go deeper on NCT00702468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00702468.